E3 ubiquitin ligases and their control of T cell autoreactivity by Bonnevier, Jody L et al.
233
AP-1 = activating protein 1; APECED = autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy; CBC = Cullin-Elongin BC-
SOCS/VHL; CHIP = carboxyl terminus of Hsc70-interacting protein; E1= ubiquitin-activating enzyme; E2 = ubiquitin-conjugating enzyme; E3 =
ubiquitin ligase; GRAIL = gene related to anergy in lymphocytes; HECT = homologous to E6-associated protein carboxyl terminus; HIF = hypoxia
inducible factor; IFN = interferon; IL = interleukin; NFκB = nuclear factor κB; NF-AT = nuclear factor of activated T cells; PA = protease-associated;
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Abstract
A loss of T cell tolerance underlies the development of most
autoimmune diseases. The design of therapeutic strategies to re-
institute immune tolerance, however, is hampered by uncertainty
regarding the molecular mechanisms involved in the inactivation of
potentially autoreactive T cells. Recently, E3 ubiquitin ligases have
been shown to mediate the development of a durable state of
unresponsiveness in T cells called clonal anergy. In this review, we
will discuss the mechanisms used by E3 ligases to control the
activation of T cells and prevent the development of autoimmunity.
Introduction
Autoreactive T cells are involved in the development of most
autoimmune diseases. Consequently, the induction and
maintenance of T cell tolerance to self-antigens is as
important to the normal function of the immune system as is
the activation of T cells in the presence of pathogens.
Despite the enormous effort that has already been made to
understand the biochemical and cellular mechanisms that
lead to the development of immune tolerance in model
systems, we do not yet understand how to re-institute
immune self tolerance in individuals that have already
developed autoimmune disease. Therefore, a better
understanding of the molecular processes involved in this
immunological decision-making offers the possibility of
defining new therapeutic targets and designing new agents
that can better promote a state of immunological self
tolerance and more effectively treat clinical autoimmunity.
In this review, we will discuss a novel form of T cell regulation
that involves a post-translational modification of proteins by
ubiquitination. This system of protein ubiquitination plays a
key role in many cellular processes, such as the regulation of
the cell cycle, modulation of cell surface receptors, cellular
differentiation, DNA repair, gene transcription, and cellular
stress responses. In the innate immune system, ubiquitin-
dependent proteasomal degradation of foreign proteins
mediates antigen presentation. Furthermore, the activation of
the proinflammatory cytokine gene transactivator nuclear
factor κB (NFκB) relies on ubiquitin-mediated degradation of
the IκBα inhibitory protein at sites of infection and/or
inflammation. Recently, protein ubiquitination has been shown
to mediate several important molecular functions in T cells
that are linked to the avoidance or development of
autoimmunity. Below, enzymes important to the regulation of
protein ubiquitination in T cells will be described and their
roles as negative regulators of autoimmunity will be
considered in more detail.
Ubiquitin biochemistry
Ubiquitin is a highly conserved 76 amino acid globular protein
that is attached to substrate proteins to modify a variety of
cellular processes. Although first described as a mechanism
for proteolysis of misfolded or damaged proteins, ubiquitina-
tion is now appreciated as an important modification for
cellular trafficking and transcriptional activation, as well as for
proteasomal- and lysosomal-mediated degradation of
signaling intermediates in the regulation of normal cell
function. Ubiquitination is accomplished through a series of
enzymatic steps involving a ubiquitin-activating enzyme
(called E1), a ubiquitin-conjugating enzyme (E2), and a
ubiquitin ligase (E3), resulting in the transfer of covalently
bound ubiquitin from the E2 protein to a lysine residue on the
target protein [1]. While mammals have only one confirmed
E1, there are over 30 E2 enzymes and many more E3 ligases,
and this allows for the ubiquitination system to confer
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substrate specificity on the many cellular processes
controlled by ubiquitin modification [2].
Different patterns of covalent attachment of ubiquitin to target
proteins provide a further level of specificity to regulation of
cellular processes by ubiquitination. E3 ligases may attach
one or more ubiquitin polypeptides to lysine residues of the
target protein in order to direct degradation, transport, or
function. For recognition and degradation by the 26S
proteasome, substrates are polyubiquitinated in that four or
more ubiquitins form a chain by ligating the carboxyl terminus
of free ubiquitin to Lys48 of the previously attached ubiquitin
protein [3]. In contrast, monoubiquitination of target protein
lysine residues results in altered trafficking to the endosome
or lysosome [4]. Substrate proteins may also be multi-
ubiquitinated with the ubiquitin chains ligating the Lys63 or
Lys39 residue of the previously attached ubiquitin, resulting
in altered transport or function of the target protein [5].
All E3 ligases are functionally similar in that they contain a
domain for recognition and binding of the E2 ubiquitin
conjugating enzyme, a catalytic domain for the transfer of
ubiquitin from the E2 to the target protein, and one or more
protein-protein interaction domains for substrate recognition
and binding (Fig. 1) [2]. E3 ligases, however, may be either
multi-protein complexes or single proteins containing all of
these functional domains. There are three types of E3 ligases
known to function in the immune system: the really interesting
new gene (RING) proteins, homologous to E6-associated
protein carboxyl terminus (HECT), and U-box. These enzymes
can act either to enhance immunity or dampen T cell
responses.
Polymeric RING E3 ligases and the positive
regulation of T cell function
SCF
Skp1-Cullin1-F-box (SCF) represents the prototypical multi-
protein E3 ligase complex composed of a Cullin1 backbone
linked to the Skp1 adaptor protein and an F-box protein that
acts as a substrate receptor to recruit specific target proteins
[6]. Cullin1 also binds the RING protein Roc1, which recruits
an E2 ubiquitin-conjugating enzyme. Specificity is achieved
Figure 1
Multi-subunit and single-chain E3 ligases that regulate T cell function. (a) Multi-subunit E3 ligases (Skp1-Cullin-F-box (SCF), Cullin-Elongin
BC-SOCS/VHL (CBC), and U-box) are anchored by a Cullin scaffold protein and recruit an E2 ubiquitin-conjugating enzyme via a Roc1 or Rbx
RING protein (as shown in blue). Substrate specificity is determined by the binding of the target protein (either with or without the carboxyl
terminus of Hsc70-interacting protein (CHIP) and Hsc70 containing pre-ubiquitin complex) to a particular F-box (e.g., Skp2), suppressor of
cytokine signaling (SOCS), or von Hippel-Lindau (VHL) protein (red), and is mediated by a Skp1 or Elongin BC adapter protein [6,15,29]. 
(b) Single-chain E3 ligases contain RING or homologous to E6-associated protein carboxyl terminus (HECT) E2 recruitment (blue) and substrate
binding (red) domains within one polypeptide [31,50,93]. The question mark on the putative GRAIL target protein indicates that no substrate has
yet been identified. C2, Ca2+ binding; PA, protease-associated; Pro, proline rich; TKB, tyrosine kinase binding; TM, transmembrane; UBA, ubiquitin-
associated; WW, two tryptophan repeat.235
through the orchestrated expression of a unique F-box protein
and the activation-dependent phosphorylation of the
particular substrate protein.
Two F-box proteins associated with the SCF complex, Skp2
and  βTrCP, positively regulate T cell activation. SCFSkp2
catalyzes the ubiquitination of p27kip1, which is a cyclin-
dependent kinase inhibitor that negatively regulates cell cycle
progression by binding to cyclin/cdk complexes and holding
them inactive in quiescent cells [7]. When the cell cycle is
initiated, p27kip1 is phosphorylated, ubiquitinated by SCFSkp2,
subsequently degraded via the proteasomal pathway [8,9],
and then cyclin/cdk is released. The end result is a cyclin/
cdk-dependent G1/S phase transition and T cell proliferation.
βTrCP is a second F-box protein that forms a complex with
SCF and positively regulates T cell NFκB activation. NFκB
family members form dimeric transcription factors that are
rapidly induced by a number of stimuli and result in
transcriptional activation of genes important for T cell
activation and survival [10]. In resting T cells, cytoplasmic
NFκB is bound by IκBα and held inactive. Upon stimulation
via the tumor necrosis factor-α receptor or a combination of T
cell antigen receptor (TCR) and CD28 ligands, IκBα is
phosphorylated by IKK on Ser32 and Ser36, thus forming a
docking site for the F-box protein SCFβTrCP [11,12].
Ubiquitinated IκBα is then targeted to the 26S proteasome
for destruction, and NFκB is released to translocate to the
nucleus [13]. Without SCFβTrCP, T cells demonstrate defective
IκBα degradation and reduced NFκB activation [14].
Negative regulation of T cell function by
polymeric RING E3 ligases
CBC
Another multi-protein RING E3 ubiquitin ligase family is
composed of Cullin-Elongin BC-SOCS/VHL (CBC) proteins
and acts to negatively regulate the activation, differentiation,
and function of T cells. CBC is composed of a Cullin scaffold
bound to the adaptor proteins Elongin B and C, which in turn
bind to the substrate receptors suppressor of cytokine
signaling (SOCS) or von Hippel-Lindau (VHL) [6]. Cullin also
binds the RING protein Rbx to recruit E2 proteins.
SOCS
SOCS proteins function similarly to F-box proteins in that
they bridge E3 ubiquitin ligase activity (RING protein Rbx2-
Cullin5-Elongin B and C) via protein-protein interactions with
target proteins [15,16]. The eight proteins of the SOCS
family (SOCS1 to SOCS7 and CIS) contain a central SH2
domain for interaction with phospho-tyrosine residues in
target proteins, and a conserved carboxy-terminal SOCS box
to bind Elongin C and join the E3 complex [17]. SOCS
proteins bind activated cytokine receptors, janus kinases
(JAKs), and signal transducers of activated T cells (STATs),
and mediate their degradation [18]. SOCS proteins are
expressed in T cells in response to TCR or cytokine receptor
stimulation, and are thought to provide negative feedback
inhibition to cytokine receptor signaling and thereby play a
role in T cell proliferation as well as in Th1/Th2 differentiation.
SOCS3 mRNA is present in resting CD4 T cells, but is
down-modulated upon TCR stimulation [19,20]. Remarkably,
T cells transgenic for SOCS3 demonstrate decreased IL-2
production in response to TCR and CD28 costimulation,
perhaps relating to the ability of over-expressed SOCS3 to
inhibit nuclear factor of activated T cells (NF-AT) activation
and Il2 gene transcription [21,22]. Consistent with this, the
depletion of SOCS3 enhances T cell proliferation [20]. Unlike
antigen stimulation, cytokines enhance the expression of
SOCS3 in a STAT5a-dependent manner, and it then
interacts with phosphorylated IL-2 receptor (IL-2R)β to
reduce the level of phosphorylation of STAT5b and inhibit
IL-2-dependent proliferation [19,23]. Finally, IL-12-dependent
induction of Th1 differentiation and resultant IFNγ production
depends on the activation of STAT4, and this activation event
is also antagonized by SOCS3 [24]. Taken together, the
results suggest that SOCS3 may play a role in maintaining
CD4 T cells in a quiescent state in the absence of antigen,
while TCR-mediated down-regulation of SOCS3 protein early
during antigen recognition allows for the initiation of an
activation-induced proliferative response. In contrast to
SOCS3, SOCS1 and SOCS2 are normally expressed at only
low levels in naïve T cells and are up-regulated during the
course of antigen stimulation [19,20]. SOCS1 expression is
induced by IL-2, IL-4, IL-7, IL-12, IL-15 and IFNγ, and T cells
deficient in SOCS1 are hyper-proliferative to IL-2 and IL-4
[19,25], thus establishing SOCS1 as an additional feedback
inhibitor of cytokine receptor signaling in T cells.
VHL
While SOCS proteins bind an Elongin BC-Cullin5-Rbx2
complex to generate a CBC E3 ubiquitin ligase, the
substrate-binding protein VHL interacts with an Elongin BC-
Cullin2-Rbx1 complex to exert its function [15]. VHL has
been shown to promote the ubiquitin-mediated degradation
of the hypoxia inducible factor (HIF)-1α part of a transcription
factor complex that mediates the cellular response to hypoxia,
to maintain homeostasis in normoxic conditions [26,27]. Sites
of inflammation, which are known to be hypoxic, are areas of
intense T cell effector function. HIF-1α has been shown to be
upregulated in the synovium of a patient with rheumatoid
arthritis [28], perhaps indicating a loss of VHL-mediated
degradation of HIF-1α in autoimmune disease.
U-box
A novel type of multi-chain E3 ubiquitin ligase has recently
been described that incorporates the U-box protein carboxyl
terminus of Hsc70-interacting protein (CHIP) into the
SCFSkp2 complex. CHIP was identified in a yeast two-hybrid
screen for novel E3 ligases based on its ability to bind the
E2A transcription factor E47, an important mediator of Notch
signaling in lymphoid cell lineage commitment, and Smad1, a
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transforming growth factor (TGF)β receptor-regulated
transcription factor [29,30]. CHIP has been proposed to
function by assembling a pre-ubiquitin complex composed of
CHIP, its co-chaperone Hsc70, Skp2, and the target protein
E47 [29]. This complex can then bind to Skp1-Cullin1-Roc1
to form a functional E3 ubiquitin ligase.
Single-chain E3 ligases
The single chain RING and HECT E3 ubiquitin ligases
perform a similar role as the multi-chain E3s, but all of the
functional domains are contained within a single polypeptide
(Fig. 1b). The catalytic RING domain transfers ubiquitin from
the E2 ubiquitin-conjugating enzyme directly to the target
protein, whereas HECT proteins themselves accept the
ubiquitin polypeptide prior to its transfer to a target protein.
Specificity is achieved through the recognition of target
substrates via protein-protein interaction domains.
Cbl
The Cbl family E3 ligases are composed of an amino-terminal
tyrosine kinase binding domain for substrate recognition, a
RING domain, a proline-rich domain, and a carboxy-terminal
ubiquitin-associated domain [31]. Before the function of Cbl
proteins as E3 ubiquitin ligases was known, c-Cbl was
recognized as a negative regulator of TCR-mediated p56Lck
phosphorylation [32,33]. c-Cbl was subsequently shown to
ubiquitinate both TCRζ and phosphorylated p56Lck [34,35].
TCR down-modulation is reduced in c-Cbl–/–/Cbl-b–/– T cells,
suggesting that these E3 ligases mediate ligand-dependent
TCR internalization [36]. T cells deficient in both Cbl-b and c-
Cbl show enhanced proliferation and IL-2 production in
response to TCR stimulation, and the spontaneous develop-
ment of autoimmunity [36]. Therefore, Cbl proteins appear to
dampen TCR/CD28 signaling via ubiquitination of signaling
intermediates or the TCR itself.
Cbl-b and ubiquitinated target proteins accumulate at the
immunological synapse during T cell activation [37]. This has
suggested an important role for Cbl-b in the regulation of
TCR signaling. Cbl-b can physically interact with p56lck,
Slp76, Zap70, phospholipase C (PLC)γ1, Vav, and the p85
subunit of phosphoinositide 3-kinase (PI3K); however, resting
Cblb–/– T cells show no notable changes in their expression
of these proteins [38]. Nevertheless, Cbl-b does ubiquitinate
p85 during T cell activation, and this reduces its association
with TCRζ [39,40]. As CD28 costimulation has also been
linked to the activation of PI3K, Cbl-b may normally act to
antagonize CD28 downstream signaling [41]. Loss of Cbl-b
in T cells does relieve the requirement for CD28 co-
stimulatory signals to achieve maximal TCR/CD3-mediated
receptor clustering, reorganization of membrane rafts, and
filopodia formation [42]. Also consistent with this model,
Cblb–/– T cells show enhanced activation of Vav [43].
Despite these data supporting a role for Cbl-b in the counter-
regulation of CD28 signaling, genetic deficiency of CD28
cannot block the development of spontaneous autoimmunity
in Cblb–/– mice, suggesting that Cbl-b also antagonizes other
signaling pathways [44].
Deltex
Notch is particularly important for T lymphocyte maturation
and lineage commitment in the thymus [45]. In the periphery,
the ligation of Notch by ligands Delta or Jagged during
antigen presentation promotes Th1 or Th2 differentiation,
respectively [46]. Notch signaling appears necessary for
optimal T cell activation, as CD3/CD28 costimulation up-
regulates the expression of Notch, and inhibition of Notch
signaling blocks T cell proliferation and IL-2 production
[47,48]. Nevertheless, Notch signaling has also been shown
to upregulate the expression of Deltex1 [49]. Deltex1
functions as a RING-type E3 ubiquitin ligase that targets
MEKK1 for ubiquitination and proteasomal degradation
resulting in the negative regulation of TCR/CD28 signaling to
IL-2 production [50]. Interestingly, Deltex1 has been shown
to be highly expressed in unstimulated CD4+25+ T-regulatory
(Treg) cells. Both Notch4 and the Notch ligand Delta1 are
upregulated by CD3/28 stimulation of Tregs, perhaps
suggesting a mechanism whereby T-T interactions via Notch-
dependent Deltex1 induction suppress T cell activation [51].
Smurf and WWP1
The single-chain HECT E3 ligase family includes NEDD4-1,
NEDD4-2, Itch, Smurf1, Smurf 2, WWP1, WWP2, and NedL1,
in humans and mice [52]. Besides a carboxy-terminal HECT
domain for transfer of ubiquitin, these proteins contain an amino-
terminal C2 domain, which is a binding site for Ca2+ that directs
phospholipid interactions at the membrane, and multiple two-
tryptophan (WW) repeat domains, which are important for
binding to proline-rich regions of target proteins [52].
Smurf1 and WWP1 negatively regulate signaling through the
TGFβ receptor via ubiquitin-mediated degradation of
receptor-regulated effector proteins Smad1, Smad2, Smad3,
Smad5 and Smad8 as well as the TGFβ receptor itself [52].
Signaling through the TGFβ receptor is required for the
maintenance of T cell homeostasis and functions through
Smad3 to attenuate TCR/CD28-mediated IL-2 production
and proliferation [53,54]. Likewise, TGFβ production by
CD4+25+ Tregs suppresses the activation of CD25– T cells
through an activation of a TGFβ receptor-Smad2 pathway
[55]. The activation of Smurf1 E3 ligase activity leads to a
ubiquitination and degradation of both Smad proteins and
TGFβ receptors and releases the blockade of T cell
proliferation. Interestingly, cells from Smurf1-deficient mice
have recently been shown to accumulate phosphorylated
MEKK2 and JNK, indicating a physiological role for Smurf1
ubiquitination and degradation of these signaling molecules
[56]. Finally, WWP1 ubiquitinates lung Kruppel-like factor
(LKLF or KLF2) [57,58]. This protein maintains homeostasis
in CD4+ and CD8+ T cells. KLF2 levels decrease upon T cell
activation and ubiquitin-mediated degradation of the protein
by WWP1 provides a potential mechanism [59].
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NEDD4 and Itch
NEDD4 and Itch are HECT E3 ubiquitin ligases responsible
for a ubiquitin-mediated counter-regulation of NFκB in T cells.
Ligation of TCR/CD28 recruits an IKK complex to the
immunological synapse where the scaffold molecules MALT1,
Carma1, and Bcl10 bridge PKCθ activation to the induction
of NFκB [60-65]. NEDD4 and Itch can ubiquitinate Bcl10
and promote its translocation to the lysosome, where Bcl10
is then marked for destruction, and the activation of NFκB is
aborted [66]. Itch has also been shown to ubiqutinate c-Jun
and JunB and to target these nuclear factors to the lysosome
[67]. This is dependent on JNK-mediated phosphorylation
and activation of Itch [68]. Both c-Jun and JunB have the
capacity to form dimers with c-Fos and transactivate at
cytokine genes. Thus, ubiquitin-mediated degradation of
these proteins represents a potentially important negative
regulatory event.
Anergy as a T cell tolerance mechanism
Clonal anergy has been postulated to be one important
immune tolerance mechanism that relies on the inducement
of mature T cells into an unresponsive state following their
initial exposure to a peripheral self-antigen [69]. This outcome
differs greatly from that seen during a protective immune
response. For the case of T cells responding to dangerous
pathogens, continued antigen responsiveness is ensured
because antigen presentation is restricted to dendritic cells
that have detected the presence of the pathogen and its
associated toll-like receptor ligands. Consequently, antigen
presentation is accompanied by the surface expression of a
high level of ‘costimulatory’ ligands such as CD80 and CD86
on the dendritic cells. CD80 and CD86 specifically bind to
the CD28 costimulatory receptor within the immunological
synapse that forms between the T cell and the antigen-
presenting cell during antigen recognition. The end result of
this strong costimulatory interaction is a maintenance of the
high level of antigen sensitivity that is required to clear the
pathogen.
In contrast to antigen recognition during infection, the delivery
of a strong TCR signal as a consequence of self-antigen
recognition is normally unaccompanied by sufficient co-
stimulatory signaling to maintain a high level of antigen
responsiveness [70]. This development of clonal anergy
results in an inability of these cells to efficiently produce the
autocrine growth factor IL-2 and to proliferate upon re-
exposure to antigen. Unresponsiveness is actively induced by
an increase in intracellular Ca2+, and new proteins must be
made in order to establish the anergic state [71,72]. We have
also demonstrated that a fusion of anergic T cells to normal
cells fails to restore antigen responsiveness, indicating the
presence of dominant-acting repressor molecules within
anergic T cells that inhibit signal transduction to the Il2 gene
[73]. Macian et al. [74] reported that Ca2+ signaling using the
calcium ionophore ionomycin could induce a limited set of
anergy-associated genes in a NF-AT dependent manner to
render T cells tolerant of antigen. Some of these genes
appear to be involved in protein ubiquitination and,
consequently, there has recently been great interest in the
roles of E3 ubiquitin ligases as anergy factors.
Single-chain E3 ligases are newly expressed
during the induction of anergy
GRAIL
The E3 ligase called gene related to anergy in lymphocytes
(GRAIL) has been shown to be up-regulated in T cells
following clonal anergy induction [75,76]. GRAIL protein
contains a protease-associated (PA) conserved domain, a
transmembrane region, and a RING. Over-expression of
GRAIL in T hybridoma cells was initially shown to inhibit IL-2
and IL-4 secretion [75]. Similarly, constitutive expression of
the  GRAIL  gene renders naive CD4+ T cells anergic to
antigenic challenge [76]. Remarkably, an enzymatically
inactive form of GRAIL (called H2N2, based on mutations in
its highly conserved RING) functions as a dominant negative
mutant capable of inhibiting endogenous GRAIL function and
blocking the development of anergy [76]. Such H2N2 RING
mutants also fail to suppress IL-2 secretion in transfected
T cells, thus predicting a role for the GRAIL RING domain
and its associated E3 ligase activity in the counter-regulation
of Il2 gene expression following anergy induction [76]. As yet,
no GRAIL target proteins have been identified in T cells, and
the mechanism for substrate recognition has not been
elucidated. Nevertheless, GRAIL protein has been localized
to a transferrin-recycling endocytic pathway and the pharma-
cological blockade of endocytic trafficking reduces the
inhibitory actions of GRAIL [75]. Therefore, GRAIL may
function by targeting signaling proteins through its PA
domain for binding and/or ubiquitination within this endocytic
pathway.
Cbl-b
Cbl-b has been shown to antagonize TCR and CD28
signaling in T cells. The spontaneous development of
autoimmunity in Cblb–/– mice further suggested its potential
as an anergy factor responsible for maintaining self-tolerance
[38]. Subsequently, Cblb–/– CD4+ T cells were found to be
resistant to clonal anergy induction [77]. Anergic wild-type
T cells demonstrate only transient and abortive immunological
synapse formation during antigen recognition, whereas
Cblb–/–  T cells pre-treated with a calcium ionophore to
promote the development of unresponsiveness have a much
more stable interaction with the antigen-presenting cell [78].
Itch
Itchy mutant mice deficient in Itch protein activity
spontaneously develop autoimmunity, as discussed in more
detail below [79]. This apparent loss of immune self-tolerance
in mutant mice may relate to an inability to functionally
inactivate autoreactive lymphocytes, since Itch–/– T cells have
been found resistant to the induction of anergy by low doses
of ionomycin [78].
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Single chain E3 ubiquitin ligases maintain
anergic T cells in an unresponsive state
In normal resting T cells, the protein levels of Cbl-b, GRAIL,
and Itch are relatively low, and these E3 ligases normally
appear not to interfere with signaling cascades leading to
IL-2 secretion and proliferation when costimulatory signals
are abundant. Within anergic T cells, however, E3 ligase
expression is increased and/or E3 enzymes are directed to
unique cellular compartments during antigen stimulation. It
appears they then cooperate in the ubiquitination of tyrosine-
phosphorylated proteins that leads to their degradation in
lysosomes.
The exact mechanism by which these E3 ubiquitin ligases
maintain antigen unresponsiveness in anergic T cells remains
uncertain. Immediately after clonal anergy induction, T cells
demonstrate global defects in TCR signaling, including
reduced phosphorylation of TCR ζ and  ε chains, poor
activation of p56Lck, Zap70, Ras, JNK and ERK, and defective
transactivation at the Il2 gene by NFκB, activating protein 1
(AP-1), and NF-AT [70]. Following antigen re-stimulation,
anergic T cells also demonstrate an aberrant down-regulation
of phosphorylated PLCγ1, PKCθ, and RasGAP [78].
Remarkably, the activation of Itch–/– and Cblb–/– T cells fails
to induce a degradation of these signaling molecules even
after an anergy-inducing regimen [78]. Itch and its HECT
family relative NEDD4 have also been observed to trans-
locate into a detergent-resistant membrane fraction following
their stimulation of anergic T cells [78]. Itch can mono-
ubiquitinate PLCγ1, promoting its degradation within an
endocytic compartment [78]. Taken together, these findings
suggest a model in which the E3 ligases GRAIL, Cbl-b, Itch,
and NEDD4 ubiquitinate and chaperone critical proximal
signaling molecules into an endocytic pathway and direct
them away from the immunological synapse and into a lyso-
somal compartment where they are subject to degradation.
Another plausible substrate for the Itch E3 ligase activity in
anergic cells is the AP-1 component molecule JunB. Like
GRAIL, Itch localizes to an endocytic pathway during T cell
stimulation. Itch appears to specifically recognize JunB,
leading to its ubiquitination and degradation [80]. Consistent
with this, Itch and ubiquitinated JunB have been co-localized
within a lysosomal compartment following stimulation [67,81].
Itch–/– T cells do, in fact, have a slower rate of JunB turnover,
and higher JunB DNA-binding activity [80]. In anergic T cells,
dysregulated Ras function and deficient activation of the
mitogen-activated protein kinases ERK, JNK, and p38, can be
expected to result in only a limited induction of JunB protein
during antigen stimulation [82-84]. Therefore, a combination
of defective JunB gene transcription and enhanced JunB
protein turnover ultimately leads to a deficiency of AP-1-
dependent transactivation at the Il2 gene. Interestingly, JNK
has been shown to enhance the degradation of JunB through
a phosphorylation-dependent activation of Itch itself [68].
Whether the defect in JNK activation that exists in anergic T
cells tempers the ability of Itch to ubiquitinate JunB and
promote its premature degradation in the lysosome remains
unknown at this time.
By working cooperatively or sequentially, these E3 ligases
appear to target activated signaling complexes in anergic T
cells and disrupt the nascent immunological synapse and
inhibit the ongoing TCR signaling cascade. Premature
turnover of Jun family nuclear factors would also put a brake
on TCR signaling and prematurely abort the IL-2 production
and proliferative responses of anergic T cells (Fig. 2).
Autoimmunity arises from insufficient E3
ligase activity
The induction of autoimmunity is a complicated process that
generally involves the breaching of multiple checkpoints [85].
Nevertheless, the absence of a single E3 ligase activity can in
some cases lead to the spontaneous development of
autoimmune disease, perhaps via a loss of T cell tolerance to
self antigens. Mice lacking Cbl-b are characterized by the
production of autoantibodies, infiltration of activated T and B
lymphocytes into multiple organs, and resultant parenchymal
damage [38]. Furthermore, the resistance of Cbl-b-deficient
mice to anergy induction during chronic and repeated
exposure to antigen puts them at risk for high mortality due to
toxic T cell activation [77]. The absence of Cbl-b also allows
for the development of a destructive autoimmune arthritis that
can be induced with type II collagen even in the absence of
mycobacterial adjuvants [77]. Similarly, Cblb–/– mutant mice
are highly susceptible to the induction of experimental
autoimmune encephalomyelitis, a mouse model of multiple
sclerosis [43]. A Cblb locus point mutation, which leads to
the expression of a truncated form of the Cbl-b protein
lacking E3 ligase activity, has been detected in Komeda
diabetes-prone rats [86]. In one human study of patients with
type I diabetes plus a second autoimmune disease, a CBLB
exon 12 single nucleotide polymorphism was also shown to
be significantly associated with disease occurrence [87].
Itchy mice demonstrate diverse immune disorders, including
chronic inflammation of the pulmonary interstitia and alveolar
proteinosis, inflammation of the glandular stomach tissue, as
well as skin inflammation resulting in scarring due to constant
itching. These mice also exhibit severe lymphoid hyperplasia
and die at age 6 to 8 months [79,80]. Itch does not appear to
be involved in T cell development in the thymus, but Itch–/–
T cells become chronically activated as the mouse ages [80].
Similar to Cbl-b, Itch–/– T cells show resistance to clonal
anergy induction [78]. No human autoimmune disease has
yet been linked to the ITCH locus.
In mice, the homozygous genomic disruption of Socs1 is
lethal. However, Socs1+/– female mice, as well as Socs1–/–
mice made transgenic for a low level of SOCS1 in the
lymphoid compartment using a Eµ promoter, survive into
adulthood but develop a lupus-like syndrome, including the
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expression of double-stranded DNA antibodies and immune-
complex glomerulonephritis [88]. In these animals, CD4+ T
cells showed enhanced proliferative responses to IL-2.
CD4–/– Socs1–/– double knockout mice lacking CD4+ T cells
were protected from autoimmunity. Thus, SOCS1 function in
CD4+ T cells may prove to facilitate an induction of anergy in
response to self-antigen recognition.
Other E3 ligases have been genetically linked to autoimmune
disease. A mutation in the autoimmune regulator (AIRE) gene
is responsible for the development of autoimmune-polyendo-
crinopathy-candidiasis-ectodermal dystrophy (APECED), an
organ-specific autoimmune disease with autosomal recessive
inheritance [89,90]. Recently, AIRE protein was identified as
an E3 ligase and APECED disease-causing mutations abolish
its ubiquitin ligase activity [91]. Significant association of
rheumatoid arthritis has also been observed with an intron 3
single nucleotide polymorphism from the CUL1 gene. CUL1
is important to proliferation and for the induction of IL-8
secretion during T cell activation [92]. Interestingly, the
intron 3 sequence polymorphism found to be associated with
rheumatoid arthritis demonstrates a greater DNA enhancer
activity than an intron 3 sequence having no association with
rheumatoid arthritis, perhaps suggesting that increased
expression of this E3 ligase can contribute to the excessive
T cell activation and loss of tolerance observed in this
autoimmune disease.
In summary, these data indicate that the aberrant expression
or function of any one of several E3 ubiquitin ligases is
sufficient to initiate or prolong a T cell response that is
directed against a self-antigen. As regulators of T cell
activation, E3 ubiquitin ligases normally set an appropriate
threshold for T cell activation to allow for a protective immune
response against pathogens while preventing the onset of
clinically important autoimmune disease. Dysregulation of one
or more of these ubiquitination pathways in the human
immune system, therefore, may pose the risk of a loss of
immune self-tolerance.
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